Aetna modified CPB 0365 covering Whipple resection (pancreaticoduodenectomy), effective September 26, 2025. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its Whipple resection coverage policy under CPB 0365 Aetna system to clarify medical necessity criteria, expand the covered indications list, and add explicit coverage for Braun enteroenterostomy and pancreatic duct stents as adjunct procedures. The primary CPT codes affected include 48150, 48152, 48153, and 48154 for the core resection, plus 44130 for Braun enteroenterostomy. One billing note embedded in the policy carries real financial risk: fibrin sealant used during the procedure is not separately reimbursed.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Pancreaticoduodenectomy (Whipple Resection) |
| Policy Code | CPB 0365 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | General Surgery, Hepatobiliary Surgery, Surgical Oncology, Gastroenterology, Trauma Surgery |
| Key Action | Audit charge capture to remove fibrin sealant as a separate line item; confirm ICD-10 codes map to covered indications before claim submission |
Aetna Whipple Resection Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy designates pancreaticoduodenectomy as medically necessary for eight specific conditions. That list matters because it's exhaustive — if your patient's diagnosis isn't on it, expect a denial.
The eight covered indications are:
| # | Covered Indication |
|---|---|
| 1 | Ampullary adenoma or carcinoma |
| 2 | Cholangiocarcinoma |
| 3 | Chronic pancreatitis |
| 4 | Combined pancreatic and duodenal injury |
| 5 | Duodenal neoplasm |
| 6 | Intraductal papillary mucinous neoplasm (IPMN) of the pancreas with high-grade dysplasia or invasive cancer |
| 7 | Neuroendocrine tumors |
| 8 | Pancreatic adenocarcinoma |
The IPMN criterion deserves attention. Aetna covers the procedure only when IPMN has progressed to high-grade dysplasia or invasive cancer. Low-grade IPMN doesn't qualify. If you're billing for a patient with incidentally found IPMN without confirmed high-grade dysplasia, that claim will not survive scrutiny. Your documentation needs to reflect pathology-confirmed staging before you submit.
The CPT codes covered when these criteria are met — 48150, 48152, 48153, and 48154 — each represent procedural variants of the same surgery. The difference between 48150 and 48152 is whether pancreatojejunostomy is performed. The difference between 48153 and 48154 is the same. Use the code that matches what was actually done.
CPB 0365 also covers two adjunct procedures tied to Whipple resection outcomes. Braun enteroenterostomy (CPT 44130) is medically necessary for reducing delayed gastric emptying following the procedure. Pancreatic duct stents are covered for prevention of post-operative pancreatic fistula. These aren't optional add-ons — Aetna explicitly covers them when the clinical rationale is documented.
This coverage policy does not mention prior authorization requirements for the procedure itself, but given the complexity and cost of a Whipple resection, confirm prior auth requirements for each specific plan. Commercial plan benefits vary, and a coverage policy doesn't override plan-level prior authorization rules.
Aetna Whipple Resection Exclusions and Non-Covered Indications
Aetna considers pancreaticoduodenectomy experimental, investigational, or unproven for Zollinger-Ellison syndrome. This is an explicit exclusion, not a documentation gap you can bridge with better notes.
The rationale Aetna cites: the clinical value of the procedure in this setting isn't established, and the morbidity and mortality risk may outweigh any potential benefit. ICD-10 code E16.4 (Increased secretion of gastrin, Zollinger-Ellison syndrome) appears in the policy's code list — but its presence there is a flag, not an approval. Any claim pairing CPT 48150–48154 with E16.4 as the primary diagnosis is heading for a claim denial.
The fibrin sealant exclusion is the other one to watch. Aetna's position: fibrin sealant is integral to the pancreaticoduodenectomy procedure and not separately reimbursed. That's a bundling decision. If your charge capture is currently pulling fibrin sealant as a separate line item, pull it before September 26, 2025. Billing it separately isn't a gray area — Aetna has stated their position clearly.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Ampullary adenoma/carcinoma | Covered | C24.1, D13.5 | CPT 48150–48154 when criteria met |
| Cholangiocarcinoma | Covered | C22.1, C24.0 | CPT 48150–48154 when criteria met |
| Chronic pancreatitis | Covered | K86.0, K86.1 | CPT 48150–48154 when criteria met |
| Combined pancreatic/duodenal injury | Covered | S36.200A–S36.299S, S36.400A–S36.490S | Trauma indications covered |
| Duodenal neoplasm | Covered | C17.0, D13.2, D37.2 | CPT 48150–48154 when criteria met |
| IPMN with high-grade dysplasia or invasive cancer | Covered | D13.6, C25.0–C25.9 | High-grade dysplasia or invasive cancer required; low-grade IPMN not covered |
| Neuroendocrine tumors | Covered | C7A.00–C7B.8, D3A.010, D3A.8 | CPT 48150–48154 when criteria met |
| Pancreatic adenocarcinoma | Covered | C25.0–C25.9 | Full pancreatic subcategory range covered |
| Delayed gastric emptying (post-Whipple) | Covered — adjunct | K91.89 | CPT 44130 Braun enteroenterostomy |
| Post-op pancreatic fistula prevention | Covered — adjunct | — | Pancreatic duct stents covered |
| Zollinger-Ellison syndrome | Not Covered / Experimental | E16.4 | Procedure considered unproven for this indication |
| Fibrin sealant (used during procedure) | Not Separately Reimbursed | — | Considered integral; bill as part of procedure, not a separate line item |
Aetna Whipple Resection Billing Guidelines and Action Items 2025
1. Remove fibrin sealant from separate charge capture before September 26, 2025.
Aetna is explicit that fibrin sealant is integral to the procedure. Check your charge description master and your surgery charge capture templates. Any facility or physician practice currently coding fibrin sealant as a separate charge needs to fix that now.
2. Confirm CPT code selection matches operative documentation.
CPT 48150 covers Whipple with pancreatojejunostomy. CPT 48152 covers the same procedure without pancreatojejunostomy. CPT 48153 covers near-total duodenectomy with choledochoenterostomy and duodenojejunostomy. CPT 48154 covers the same without pancreatojejunostomy. The op note has to support whichever code you use.
3. Verify ICD-10 diagnosis coding maps to a covered indication.
E16.4 (Zollinger-Ellison syndrome) with Whipple CPT codes is a denial waiting to happen. For IPMN cases, your claim needs a code that reflects the malignant or high-grade status — not a benign neoplasm code like D13.6 alone if the pathology shows high-grade dysplasia or invasion.
4. Add CPT 44130 to claims when Braun enteroenterostomy is performed.
This is explicitly covered. If your surgeons are performing Braun enteroenterostomy to reduce delayed gastric emptying, that charge belongs on the claim with K91.89 supporting the indication. Don't leave that reimbursement on the table.
5. Document pancreatic duct stent placement for post-operative fistula prevention.
Aetna covers stent use for this specific purpose. The claim needs to reflect that the stent was placed for fistula prevention — not just a generic post-operative stent. Tie the operative and procedure notes to that indication explicitly.
6. Review omental flap and biliary catheter charges against policy intent.
CPT 49905 (omental flap) and CPT 47533–47536 (biliary drainage catheters) appear in the policy as "other CPT codes related to the CPB." These are related but not automatically covered as part of the resection. Know the distinction before bundling or separately billing these codes.
7. Check liquid biopsy panel codes against plan benefits before ordering.
CPT 81462, 81463, and 81464 (solid organ neoplasm genomic sequence analysis) appear in the policy code list as related codes. Coverage for these liquid biopsy panels varies by plan. Do not assume inclusion in the Whipple procedure coverage. Verify plan-level benefits before billing. If you're not sure how these apply to your payer mix, talk to your billing consultant or compliance officer before the September 26, 2025 effective date.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Pancreaticoduodenectomy Under CPB 0365
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 44130 | CPT | Enteroenterostomy, anastomosis of intestine, with or without cutaneous enterostomy (separate procedure) |
| 48150 | CPT | Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy and pancreaticojejunostomy (Whipple-type procedure) |
| 48152 | CPT | Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy — without pancreatojejunostomy |
| 48153 | CPT | Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and duodenojejunostomy |
| 48154 | CPT | Pancreatectomy, proximal subtotal with near-total duodenectomy — without pancreatojejunostomy |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| C17.0 | Malignant neoplasm of duodenum |
| C22.1 | Intrahepatic bile duct carcinoma |
| C24.0 | Malignant neoplasm of extrahepatic bile duct |
| C24.1 | Malignant neoplasm of ampulla of Vater |
| C25.0 | Malignant neoplasm of head of pancreas |
| C25.1 | Malignant neoplasm of body of pancreas |
| C25.2 | Malignant neoplasm of tail of pancreas |
| C25.3 | Malignant neoplasm of pancreatic duct |
| C25.4 | Malignant neoplasm of endocrine pancreas |
| C25.5 | Malignant neoplasm of other specified parts of pancreas |
| C25.6 | Malignant neoplasm of body and tail of pancreas |
| C25.7 | Malignant neoplasm of other parts of pancreas |
| C25.8 | Malignant neoplasm of overlapping sites of pancreas |
| C25.9 | Malignant neoplasm of pancreas, unspecified |
| C7A.00–C7B.8 | Neuroendocrine tumors (range) |
| D01.49 | Carcinoma in situ of other parts of intestine |
| D01.5 | Carcinoma in situ of liver, gallbladder, and bile ducts |
| D13.2 | Benign neoplasm of duodenum |
| D13.5 | Benign neoplasm of extrahepatic bile ducts |
| D13.6 | Benign neoplasm of pancreas |
| D13.7 | Benign neoplasm of endocrine pancreas |
| D37.2 | Neoplasm of uncertain behavior of small intestine |
| D37.6 | Neoplasm of uncertain behavior of liver, gallbladder, and bile ducts |
| D3A.010 | Benign carcinoid tumor of the duodenum |
| D3A.8 | Other benign neuroendocrine tumors |
| E16.4 | Increased secretion of gastrin (Zollinger-Ellison syndrome) — NOT covered for Whipple |
| K86.0 | Alcohol-induced chronic pancreatitis |
| K86.1 | Other chronic pancreatitis |
| K91.89 | Other postprocedural complications and disorders of digestive system (delayed gastric emptying following Whipple) |
| S36.200A–S36.299S | Injury of pancreas (range) |
| S36.400A–S36.400S | Unspecified injury of duodenum |
| S36.410A–S36.410S | Primary blast injury of duodenum |
| S36.420A–S36.420S | Contusion of duodenum |
| S36.430A–S36.430S | Laceration of duodenum |
| S36.490A–S36.490S | Other injury of duodenum |
Get the Full Picture for CPT 44130
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.